CXCR2 and rhabdomyosarcoma: Disrupting MDSC and Treg trafficking, using inhibitors to CXCR2 and CXCR4, has been shown to enhance anti-PD-1 tumor response in rhabdomyosarcoma and hepatocellular carcinoma murine models, respectively [29,93].